Open access
Open access
Powered by Google Translator Translator

Oncology – Skin

Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.

23 Jun, 2022 | 09:57h | UTC

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment – Journal of Clinical Oncology

 


ASCO Guideline Update: Systemic therapy for melanoma.

14 Jun, 2022 | 11:00h | UTC

Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 


Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.

10 Jun, 2022 | 10:28h | UTC

Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review – The Lancet Digital Health

 

Commentary on Twitter

 


RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.

2 Jun, 2022 | 10:41h | UTC

Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial – JAMA Dermatology

 

Commentary on Twitter

 


Review: Managing metastatic melanoma in 2022.

19 May, 2022 | 10:23h | UTC

Managing Metastatic Melanoma in 2022: A Clinical Review – JCO Oncology Practice

 

Commentary on Twitter

 


Cohort Study: Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis.

5 May, 2022 | 10:14h | UTC

Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis – JAMA Dermatology (link to abstract – $ for full-text)

Author Interview: Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis

News Release: Patients with rare skin cancer, Merkel cell carcinoma, face 40% recurrence rate – University of Washington School of Medicine

Commentary: #VisualAbstract: Stage-specific and time-specific recurrence data can help determine need for surveillance in Merkel cell carcinoma patients – Physician’s Weekly/2 Minute Medicine

 

Commentary on Twitter

 


Guidelines: Cutaneous lymphomas.

25 Apr, 2022 | 00:38h | UTC

S2k-Guidelines – Cutaneous lymphomas (ICD10 C82 – C86): Update 2021 – Journal of the German Society of Dermatology

 


RCT: Pembrolizumab vs. placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma.

4 Apr, 2022 | 00:56h | UTC

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


Global burden of cutaneous melanoma in 2020 and projections to 2040.

31 Mar, 2022 | 08:11h | UTC

Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (free for a limited period)

Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (free for a limited period)

Commentary: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay

 


Review | Imaging findings of malignant skin tumors: radiological–pathological correlation.

25 Mar, 2022 | 08:40h | UTC

Imaging findings of malignant skin tumors: radiological–pathological correlation – Insights into Imaging

 


Estimating overdiagnosis of melanoma using trends among black and white patients in the US.

24 Mar, 2022 | 08:52h | UTC

Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Deadly form of skin cancer ‘overdiagnosed’ in some patients, study finds – UPI

 

Commentary from the author on Twitter (thread – click for more)

 


Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say?

22 Mar, 2022 | 08:03h | UTC

Vitamin B3, niacinamide and reducing skin cancer risk: what does the research say? – The Conversation

Related: A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention – New England Journal of Medicine

 


NCCN Guidelines Insights: Squamous Cell Skin Cancer, Version 1.2022.

7 Feb, 2022 | 08:34h | UTC

NCCN Guidelines Insights: Squamous Cell Skin Cancer, Version 1.2022 – Journal of the National Comprehensive Cancer Network

 


Guideline: atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).

3 Feb, 2022 | 08:48h | UTC

S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) – Journal of the German Society of Dermatology

 


RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.

18 Jan, 2022 | 09:08h | UTC

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)

 


RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).

12 Jan, 2022 | 08:43h | UTC

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma – University of Texas M. D. Anderson Cancer Center

 

Commentary on Twitter

 


RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.

5 Dec, 2021 | 23:07h | UTC

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma – Journal of Clinical Oncology

Editorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology

Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


Guideline on Cutaneous Angiosarcomas – Update 2021.

26 Nov, 2021 | 10:00h | UTC

S1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology

 


Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.

16 Nov, 2021 | 08:14h | UTC

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases

Related: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.

28 Sep, 2021 | 09:03h | UTC

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma – New England Journal of Medicine

 

Commentary on Twitter

 


Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?

22 Aug, 2021 | 22:16h | UTC

Sentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)

 


US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.

15 Jul, 2021 | 09:11h | UTC

Report: Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics – JNCI: Journal of the National Cancer Institute

News release: Annual Report to the Nation: Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate – National Cancer Institute

Commentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society

 


Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.

15 Jun, 2021 | 08:49h | UTC

Active Surveillance as a Management Option for Low-risk Basal Cell Carcinoma – JAMA Internal Medicine

 


An epidemic of overdiagnosis: Melanoma diagnoses sky rocket

20 Jan, 2021 | 01:30h | UTC

An epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis

Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)

Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)

 


Stay Updated in Your Specialty

No spam, just news.